Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.68 |
| ▸ | RAB9A | P51151 | 6/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.68 |
| ▸ | RELA | Q04206 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | INMT | O95050 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11731030 | 0.77 | MAPT (0.56) | SMN1; SMN2RAB9AMAPTKDM4ENPC1 | |
| SCHEMBL4337912 | 0.73 | RAB9A (0.71) | SMN1; SMN2RAB9AMAPTKDM4ENPC1 | |
| SCHEMBL7852222 | 0.72 | MAPT (0.50) | SMN1; SMN2RAB9AMAPTKDM4ENPC1 | |
| SCHEMBL25002012 | 0.71 | CHRNA1 (0.60) | SMN1; SMN2RAB9AMAPTKDM4ENPC1 | |
| SCHEMBL9413138 | 0.71 | MAPT (0.56) | SMN1; SMN2RAB9AMAPTKDM4ENPC1 | |
| SCHEMBL4875267 | 0.70 | ALDH1A1 (0.79) | SMN1; SMN2MAPTKDM4ETDP1ALDH1A1 | |
| SCHEMBL25003076 | 0.69 | INMT (0.51) | SMN1; SMN2RAB9AMAPTKDM4ENPC1 | |
| SCHEMBL6939772 | 0.69 | ALDH1A1 (0.46) | SMN1; SMN2RAB9AMAPTKDM4ELMNA | |
| SCHEMBL10722832 | 0.69 | GAA (0.46) | SMN1; SMN2KDM4ELMNAALDH1A1KMT2A | |
| SCHEMBL1820216 | 0.69 | ALDH1A1 (0.46) | SMN1; SMN2RAB9AMAPTKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134848-A1 | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-07-17 | — | — | US | claimed |
| CN-1366521-A | Substituted 1-aza-2-imino heterocycles and their use as nicotinic acetylcholine receptors activators | SUNTORY LTD (JP) | 2002-08-28 | — | — | CN | claimed |
| EP-1185521-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS ACTIVATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | SUNTORY LIMITED (JP) | 2002-03-13 | — | — | EP | claimed |
| WO-2001081326-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTORS ACTIVATORS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | claimed |
| US-20030134848-A1 | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-1185521-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS ACTIVATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | SUNTORY LIMITED (JP) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001081326-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTORS ACTIVATORS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134848-A1 | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators | CHRNA7, CHRNA2, CHRNA1 | SMN1; SMN2 2165/4885RAB9A 3993/4885MAPT 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.